Multiple sclerosis (MS) is a chronic, immune-mediated, neurodegenerative condition that results in progressive accumulation of disability over the course of the disease. MS presents heterogeneously, ...

Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial. ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with ...

The European Commission has approved Wayrilz, a novel, oral, reversible, Bruton’s tyrosine kinase inhibitor, as a new treatment for immune ...

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of ...

The Understanding the Pathway article by Wiestner, entitled "Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses ...

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...

Scientists at NYU Langone Health, its Perlmutter Cancer Center, and collaborators report that an activity pattern in certain genes responsible for building spleen tyrosine kinases can predict which ...

An activity pattern in certain genes responsible for building proteins known as spleen tyrosine kinases can predict which melanoma patients are likely to have severe side effects from immunotherapy ...

There has been much speculation on the potential use of kinase inhibitors for the treatment of autoimmune rheumatic diseases. Investigations of small-molecule inhibitors of p38 mitogen-activated ...